2000
Cerebrospinal Fluid Corticotropin-Releasing Hormone in Healthy Humans: Effects of Yohimbine and Naloxone1
Vythilingam M, Anderson G, Owens M, Halaszynski T, Bremner J, Carpenter L, Heninger G, Nemeroff C, Charney D. Cerebrospinal Fluid Corticotropin-Releasing Hormone in Healthy Humans: Effects of Yohimbine and Naloxone1. The Journal Of Clinical Endocrinology & Metabolism 2000, 85: 4138-4145. PMID: 11095445, DOI: 10.1210/jcem.85.11.6968.Peer-Reviewed Original ResearchConceptsCRH neuronsParaventricular nucleusCSF CRHCerebrospinal fluidPlasma cortisolHypothalamic pituitary adrenal axis activityCSF CRH concentrationsCSF CRH levelsCorticotropin-Releasing HormoneCSF NE levelsEffects of yohimbineAdult normal volunteersPlasma cortisol concentrationsCRH concentrationsCentral norepinephrineOpioid regulationPlacebo administrationPVN neuronsCRH levelsNE levelsCSF norepinephrineHPA axisAxis activityHealthy humansMedian eminence
1996
Adenosine diphosphate inhibits the serotonin transporter
Anderson G, Hall L, Horne W, Yang J. Adenosine diphosphate inhibits the serotonin transporter. Biochimica Et Biophysica Acta 1996, 1283: 14-20. PMID: 8765089, DOI: 10.1016/0005-2736(96)00073-9.Peer-Reviewed Original Research
1992
Platelet dense granule release reaction monitored by high-performance liquid chromatography-fluorometric determination of endogenous serotonin
Anderson G, Hall L, Yang J, Cohen D. Platelet dense granule release reaction monitored by high-performance liquid chromatography-fluorometric determination of endogenous serotonin. Analytical Biochemistry 1992, 206: 64-67. PMID: 1456443, DOI: 10.1016/s0003-2697(05)80011-9.Peer-Reviewed Original ResearchDifferentiation of Neuro-2a neuroblastoma cells by an antibody to GM3 ganglioside
Chatterjee D, Chakraborty M, Anderson G. Differentiation of Neuro-2a neuroblastoma cells by an antibody to GM3 ganglioside. Brain Research 1992, 583: 31-44. PMID: 1324094, DOI: 10.1016/s0006-8993(10)80007-1.Peer-Reviewed Original ResearchMeSH KeywordsAmino AcidsAnimalsAntibodies, MonoclonalBromodeoxyuridineBucladesineCatecholaminesCell DifferentiationCell DivisionCell LineDNA ReplicationElectrophoresis, Gel, Two-DimensionalElectrophoresis, Polyacrylamide GelFluorescent Antibody TechniqueG(M3) GangliosideGangliosidesKineticsMethionineMiceModels, BiologicalMolecular WeightNeoplasm ProteinsNeuroblastomaSerotoninThymidineConceptsNeuro-2a cellsTotal cellular proteinProtein kinase A (PKA) inhibitorProtein kinase C activityInhibitors of PKCKinase C activityNeuro-2a neuroblastoma cellsCellular proteinsCellular differentiationCell surface gangliosidesElevated intracellular cAMP levelsDifferentiated cellsIntracellular cAMP levelsCyclase activityMode of actionGi proteinsProteinPKCSurface gangliosidesC activityDifferentiationAdenylate cyclase activityNeuroblastoma cellsA inhibitorsGM2 ganglioside
1987
Steady-state model for plasma free and platelet serotonin in man
Anderson G, Stevenson J, Cohen D. Steady-state model for plasma free and platelet serotonin in man. Life Sciences 1987, 41: 1777-1785. PMID: 3657383, DOI: 10.1016/0024-3205(87)90696-5.Peer-Reviewed Original Research
1986
Brief debrisoquin administration to assess central dopaminergic function in children
Riddle M, Shaywitz B, Leckman J, Anderson G, Shaywitz S, Hardin M, Ort S, Cohen D. Brief debrisoquin administration to assess central dopaminergic function in children. Life Sciences 1986, 38: 1041-1048. PMID: 3456480, DOI: 10.1016/0024-3205(86)90239-0.Peer-Reviewed Original ResearchConceptsCentral dopaminergic functionDopaminergic functionHomovanillic acid levelsBehavioral side effectsActive antihypertensive agentDebrisoquin sulfatePHVA levelsAntihypertensive agentsSix-hour periodSide effectsBrief administrationNeuropsychiatric disordersAdministration methodsMarked reductionPeripheral techniquesAcid levelsAdministrationPatientsChildrenDebrisoquinPHVA
1982
Psychopharmacology of attention deficit disorder: pharmacokinetic, neuroendocrine, and behavioral measures following acute and chronic treatment with methylphenidate.
Shaywitz S, Hunt R, Jatlow P, Cohen D, Young J, Pierce R, Anderson G, Shaywitz B. Psychopharmacology of attention deficit disorder: pharmacokinetic, neuroendocrine, and behavioral measures following acute and chronic treatment with methylphenidate. Pediatrics 1982, 69: 688-94. PMID: 7079034, DOI: 10.1542/peds.69.6.688.Peer-Reviewed Original ResearchConceptsAcute studyMPH concentrationsGrowth hormoneObserved maximal concentrationCentral dopaminergic mechanismsPeak plasma concentrationAdministration of medicationsPharmacokinetics of methylphenidatePlasma growth hormoneConcentrations of methylphenidatePlasma MPH concentrationsAttention deficit disorderClinical responseChronic treatmentDopaminergic mechanismsGroup of childrenDisorders of attentionAbbreviated Conners' Rating ScaleSchool-aged childrenOral administrationPlasma concentrationsClinical pharmacologyMPH administrationProlactin concentrationsPercentage of improvement